Hook & thesis
Covista, Inc. sits at the intersection of secular higher-education demand and cost structure optionality. The business already generates substantial free cash flow ($392.7M annual FCF) and carries moderate leverage (debt/equity about 0.46). With the shares trading around $131.83 and a PE near 17.8x, the market has priced in stability but not significant margin re-rating. We think continued enrollment stabilization, higher online mix, and operating leverage can drive above-consensus profitability and push valuation back toward the mid-20s PE multiple over the next 180 trading days.
This is an actionable, asymmetric trade: enter on a consolidation-level pullback and let margin expansion and a modest multiple expansion do the heavy lifting. The technicals align with the fundamental story - price sits above the 50-day SMA and MACD shows bullish momentum - providing an entry window with defined risk.
What Covista does and why the market should care
Covista operates post-secondary education brands across three segments: Chamberlain (nursing and health professions), Walden (broad online degrees and certificates), and Medical & Veterinary programs. These segments benefit from recurring tuition revenue and high incremental margins on online delivery. The market cares because student demand in nursing and health professions remains durable, and scale in online programs translates directly into operating leverage.
Hard numbers that matter
| Metric | Value |
|---|---|
| Current price (approx) | $131.83 |
| Market cap | $4.49B |
| EPS (TTM) | $7.39 |
| PE | ~17.8x |
| EV / EBITDA | ~10.7x |
| Free cash flow (annual) | $392.7M |
| Return on equity | ~17.4% |
| Debt / Equity | ~0.46 |
Those numbers point to a business that generates real cash, with a balance sheet that can support investments to grow online offerings without levering up. At current EPS, a re-rating from ~18x to low-20s would imply a share price comfortably above the recent 52-week high ($156.26). The company’s trailing free cash flow and ROE give credibility to that multiple expansion thesis if the market becomes more confident in sustained margin improvement.
Technical and market context
The stock is trading above its 10-, 20- and 50-day moving averages (10-day SMA ~$129.87; 50-day SMA ~$125.30), RSI around 55 and MACD indicating bullish momentum. Short interest runs around 1.65M shares against a float of roughly 33.1M shares - about 5% of the float - with days-to-cover near 4.7. That degree of short interest isn't an extreme short-squeeze setup, but it does show there are skeptics; positive execution and topline beats can compress that positioning and amplify upside. Average daily volume sits around 375k shares, so liquidity is adequate for trade entry and exit.
Catalysts
- Quarterly earnings beat and upward revision to guidance - confirms operating leverage and free cash flow strength.
- Reported enrollment growth or improved retention in nursing and health programs - directly lifts revenue and utilization.
- Margin expansion from higher online mix or cost efficiencies - translates to faster EPS growth than revenue growth.
- Positive analyst repricing - several broker targets may be conservative versus improved FCF conversion.
- Reduction in short interest after a run of outperformance - can accentuate rally on positive news.
Trade plan (actionable)
Direction: Long
Entry price: $132.00
Target price: $156.00
Stop loss: $120.00
Horizon: long term (180 trading days) - I expect this trade to play out over several quarters as enrollment data and margin trajectories become clearer. The 180-trading-day horizon lets quarterly results and updates move the story from potential to demonstrated improvement.
Rationale: Entry at $132 captures the current consolidation band, just above the 50-day moving average. Target $156 is set near prior 52-week highs and aligns with a reasonable multiple re-rating scenario: EPS of $7.39 at ~21x implies a price near $155. A stop at $120 limits downside below recent structural support and gives room for intraday noise while protecting capital if the thesis fails.
Risk / reward: Upside from $132 to $156 is $24; downside to $120 is $12. That is a 2:1 reward-to-risk ratio before costs.
Valuation framing
At a market cap near $4.49B and EV around $4.75B, Covista trades at ~10.7x EV/EBITDA and ~17.8x PE. For a cash-generative, niche-post-secondary education operator with modest leverage and ROE ~17%, those multiples are neither cheap nor frothy. The current valuation assumes steady state performance. The path to upside is clear: modest margin expansion (a few hundred basis points) plus a 3-5 point multiple expansion gets you into the mid-$150s. If management executes and FCF stays strong, the market should pay up for predictable earnings growth and higher capital returns.
Key risks and counterarguments
- Regulatory risk: Changes in higher-education regulation, accreditation standards, or federal student aid policy could materially impact enrollment and revenue.
- Enrollment volatility: A sudden slowdown in demand for online or nursing programs would compress utilization and hurt operating leverage.
- Executive selling and signaling: The CEO sold roughly 5,291 shares in June (~$690k) under a trading plan. While he still holds significant equity (reported >$55M), timing near recent highs can spook some investors.
- Competition and pricing pressure: The online degree market is competitive. Price or marketing investments to protect share would pressure margins.
- Macro sensitivity: In a recessionary environment, discretionary enrollment and employer-sponsored tuition programs can fall, hurting revenues.
Counterargument: The stock already trades near its recent range and at an ~18x PE - not a deep discount. If the market demands clear proof of sustained margin expansion rather than potential, the shares could languish or decline even if revenue is stable. Also, executive selling could be interpreted as lack of near-term conviction and spur further softness.
What would change my mind
I will turn bearish if we see any one of the following: sequential declines in enrollment across the core nursing and online programs, a material drop in free cash flow (a miss of more than $50M annualized versus the current run rate), or regulatory action that materially restricts student aid or accreditation for a major segment. Conversely, a clear multi-quarter trend of margin expansion of 200+ basis points and rising guidance would make me more aggressive, potentially raising the target toward $170 if multiples re-rate beyond the low-20s.
Bottom line: Covista is a measured long - not a momentum punt. Buy at $132 with a $120 stop and a $156 target, and give the company the time to turn enrollment and efficiency into sustainable EPS growth.